Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | OSBP | P22059 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 11/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658123 | 1.00 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1050027 | 1.00 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1081197 | 1.00 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| Hydrochloric Acid SCHEMBL11907786 | 0.99 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL14056349 | 0.92 | USP2 (0.57) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19692309 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19691912 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL998341 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL3359948 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2440566 | 0.90 | OSBP (0.58) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956278-B2 | Multivalent meningococcal conjugates and methods for preparing conjugates | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017189448-A1 | BIVALENT IMMUNOGENIC CONJUGATE FOR MALARIA AND TYPHOID | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20160331824-A1 | MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING CONJUGATES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-11-17 | — | — | US | disclosed |
| US-9427476-B2 | Multivalent meningococcal conjugates and methods for preparing conjugates | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150110829-A1 | MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING CONJUGATES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-04-23 | — | — | US | disclosed |
| WO-2013177397-A1 | MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING COJUGATES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2000012114-A1 | PEPTIDE SCAFFOLDS FOR TRANSFER OF MOLECULES INTO EUKARYOTIC CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331824-A1 | MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING CONJUGATES | C1QBP, CFB, CFH | USP2 1699/4885CYP46A1 3725/4885LMNA 1569/4885 |
| US-20150110829-A1 | MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING CONJUGATES | C1QBP, CFB, CFH | USP2 1699/4885CYP46A1 3725/4885LMNA 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.